19.07.2011 • NewsJoseph JimenezNovartisQ2 2011

Novartis Posts Higher Q2 Profit

Novartis reported second-quarter net income of $2.73 billion or $1.13 per share versus $2.44 billion or $1.06 per share in the year-ago quarter.
Core net income for the quarter increased to $3.56 billion or $1.48 per share from $2 77 billion or $1.20 per share in the previous year.
Quarterly sales climbed to $14.92 billion from $11.72 billion in the prior year.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.40 per share on revenues of $14.42 billion for the quarter. Analysts' estimates typically exclude special items.

Joseph Jimenez, chief executive officer of Novartis, commented, "We achieved strong sales growth of 19% in constant currencies and margin improvement of 0.4 percentage points in U.S. dollars. We further demonstrated the success of our R&D strategy with four major approvals and two filings in the second quarter. Our diversified healthcare portfolio, focused on high growth segments, is enabling us to generate superior results."

 

Company

Novartis Pharma GmbH

Roonstr. 25
90429 Nürnberg

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.